CARA stock forecast
Our latest prediction for CARA Therapeutics, Inc.'s stock price was made on the June 3, 2020 when the stock price was at 16.07$.
In the short term (2weeks), CARA's stock price should underperform the market by -1.86%. During that period the price should oscillate between -9.52% and +9.67%.
In the medium term (3months), CARA's stock price should underperform the market by -6.59%. During that period the price should oscillate between -36.58% and +22.22%.Get email alerts
Create a solid portfolio with CARA
About CARA Therapeutics, Inc.
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
At the moment the company generates 24M USD in revenues.
On its last earning announcement, the company reported a loss of -2.54$ per share.
The book value per share is 1.86$
Three months stock forecastJune 3, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|